Guaiacol as a drug candidate for treating adult polyglucosan body disease
Adult polyglucosan body disease (APBD) is a late-onset disease caused by intracellular accumulation of polyglucosan bodies, formed due to glycogen-branching enzyme (GBE) deficiency. To find a treatment for APBD, we screened 1,700 FDA-approved compounds in fibroblasts derived from APBD-modeling GBE1-...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Society for Clinical Investigation
2018
|
| _version_ | 1797095830564372480 |
|---|---|
| author | Kakhlon, O Ferreira, I Solmesky, L Khazanov, N Lossos, A Alvarez, R Yetil, D Pampou, S Weil, M Senderowitz, H Escriba, P Yue, W Akman, H |
| author_facet | Kakhlon, O Ferreira, I Solmesky, L Khazanov, N Lossos, A Alvarez, R Yetil, D Pampou, S Weil, M Senderowitz, H Escriba, P Yue, W Akman, H |
| author_sort | Kakhlon, O |
| collection | OXFORD |
| description | Adult polyglucosan body disease (APBD) is a late-onset disease caused by intracellular accumulation of polyglucosan bodies, formed due to glycogen-branching enzyme (GBE) deficiency. To find a treatment for APBD, we screened 1,700 FDA-approved compounds in fibroblasts derived from APBD-modeling GBE1-knockin mice. Capitalizing on fluorescent periodic acid–Schiff reagent, which interacts with polyglucosans in the cell, this screen discovered that the flavoring agent guaiacol can lower polyglucosans, a result also confirmed in APBD patient fibroblasts. Biochemical assays showed that guaiacol lowers basal and glucose 6-phosphate–stimulated glycogen synthase (GYS) activity. Guaiacol also increased inactivating GYS1 phosphorylation and phosphorylation of the master activator of catabolism, AMP-dependent protein kinase. Guaiacol treatment in the APBD mouse model rescued grip strength and shorter lifespan. These treatments had no adverse effects except making the mice slightly hyperglycemic, possibly due to the reduced liver glycogen levels. In addition, treatment corrected penile prolapse in aged GBE1-knockin mice. Guaiacol’s curative effects can be explained by its reduction of polyglucosans in peripheral nerve, liver, and heart, despite a short half-life of up to 60 minutes in most tissues. Our results form the basis to use guaiacol as a treatment and prepare for the clinical trials in APBD. |
| first_indexed | 2024-03-07T04:33:34Z |
| format | Journal article |
| id | oxford-uuid:cf252429-af8f-4e78-8c32-b469f3069d0f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:33:34Z |
| publishDate | 2018 |
| publisher | American Society for Clinical Investigation |
| record_format | dspace |
| spelling | oxford-uuid:cf252429-af8f-4e78-8c32-b469f3069d0f2022-03-27T07:40:34ZGuaiacol as a drug candidate for treating adult polyglucosan body diseaseJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cf252429-af8f-4e78-8c32-b469f3069d0fEnglishSymplectic Elements at OxfordAmerican Society for Clinical Investigation2018Kakhlon, OFerreira, ISolmesky, LKhazanov, NLossos, AAlvarez, RYetil, DPampou, SWeil, MSenderowitz, HEscriba, PYue, WAkman, HAdult polyglucosan body disease (APBD) is a late-onset disease caused by intracellular accumulation of polyglucosan bodies, formed due to glycogen-branching enzyme (GBE) deficiency. To find a treatment for APBD, we screened 1,700 FDA-approved compounds in fibroblasts derived from APBD-modeling GBE1-knockin mice. Capitalizing on fluorescent periodic acid–Schiff reagent, which interacts with polyglucosans in the cell, this screen discovered that the flavoring agent guaiacol can lower polyglucosans, a result also confirmed in APBD patient fibroblasts. Biochemical assays showed that guaiacol lowers basal and glucose 6-phosphate–stimulated glycogen synthase (GYS) activity. Guaiacol also increased inactivating GYS1 phosphorylation and phosphorylation of the master activator of catabolism, AMP-dependent protein kinase. Guaiacol treatment in the APBD mouse model rescued grip strength and shorter lifespan. These treatments had no adverse effects except making the mice slightly hyperglycemic, possibly due to the reduced liver glycogen levels. In addition, treatment corrected penile prolapse in aged GBE1-knockin mice. Guaiacol’s curative effects can be explained by its reduction of polyglucosans in peripheral nerve, liver, and heart, despite a short half-life of up to 60 minutes in most tissues. Our results form the basis to use guaiacol as a treatment and prepare for the clinical trials in APBD. |
| spellingShingle | Kakhlon, O Ferreira, I Solmesky, L Khazanov, N Lossos, A Alvarez, R Yetil, D Pampou, S Weil, M Senderowitz, H Escriba, P Yue, W Akman, H Guaiacol as a drug candidate for treating adult polyglucosan body disease |
| title | Guaiacol as a drug candidate for treating adult polyglucosan body disease |
| title_full | Guaiacol as a drug candidate for treating adult polyglucosan body disease |
| title_fullStr | Guaiacol as a drug candidate for treating adult polyglucosan body disease |
| title_full_unstemmed | Guaiacol as a drug candidate for treating adult polyglucosan body disease |
| title_short | Guaiacol as a drug candidate for treating adult polyglucosan body disease |
| title_sort | guaiacol as a drug candidate for treating adult polyglucosan body disease |
| work_keys_str_mv | AT kakhlono guaiacolasadrugcandidatefortreatingadultpolyglucosanbodydisease AT ferreirai guaiacolasadrugcandidatefortreatingadultpolyglucosanbodydisease AT solmeskyl guaiacolasadrugcandidatefortreatingadultpolyglucosanbodydisease AT khazanovn guaiacolasadrugcandidatefortreatingadultpolyglucosanbodydisease AT lossosa guaiacolasadrugcandidatefortreatingadultpolyglucosanbodydisease AT alvarezr guaiacolasadrugcandidatefortreatingadultpolyglucosanbodydisease AT yetild guaiacolasadrugcandidatefortreatingadultpolyglucosanbodydisease AT pampous guaiacolasadrugcandidatefortreatingadultpolyglucosanbodydisease AT weilm guaiacolasadrugcandidatefortreatingadultpolyglucosanbodydisease AT senderowitzh guaiacolasadrugcandidatefortreatingadultpolyglucosanbodydisease AT escribap guaiacolasadrugcandidatefortreatingadultpolyglucosanbodydisease AT yuew guaiacolasadrugcandidatefortreatingadultpolyglucosanbodydisease AT akmanh guaiacolasadrugcandidatefortreatingadultpolyglucosanbodydisease |